First-Line Treatment With Aliskiren/Amlodipine Combination Provides Robust Blood Pressure Reductions in Patients With Severe Hypertension: 9A.06

Braun-Dullaeus, Rüdiger C.; Shustov, SB; Rogelio, G. G.; Zhang, J; Hristoskova, Sashka; Häring, DA; Liao, Wei-Chi

doi:10.1097/01.hjh.0000379510.67724.b9

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with the findings of previous studies. 4,7,15 Most AEs reported during the present study were mild or moderate in severity, and few patients experienced serious AEs or discontinued participation because of AEs. Overall, aliskiren/amlodipine combination therapy had a similar safety and tolerability profile to that of the individual monotherapies, with no evidence of new treatment-emergent AEs.…”

Section: Discussionmentioning

confidence: 72%

“…Previous clinical trials have demonstrated that aliskiren/ amlodipine combination therapy provides significant additional BP reductions over those obtained with amlodipine monotherapy in patients with hypertension. 7 Aliskiren/amlodipine combination therapy has also demonstrated BP-lowering efficacy during longterm treatment. 8 This study demonstrated the greater BP-lowering effect of aliskiren/amlodipine single-pill combination compared with each mono-component, indicating the contribution from each monocomponent toward combination.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study

Littlejohn

Jones²,

Zhang

et al. 2012

J Hum Hypertens

Self Cite

View full text Add to dashboard Cite

Most patients with hypertension need more than one drug to achieve blood pressure (BP) control. This randomized, double-blind, multifactorial study evaluated whether combinations of aliskiren and amlodipine provided superior BP reductions to component monotherapies in patients with hypertension (mean sitting diastolic BP (msDBP) 95-<110 mm Hg). Overall, 1688 patients were randomized to once-daily monotherapy with aliskiren 150 or 300 mg or amlodipine 5 or 10 mg, combination therapy with one of four corresponding aliskiren/amlodipine doses, or placebo for 8 weeks. At week 8 end point, aliskiren/amlodipine combinations provided significant msDBP reductions from baseline of 14.0-16.5 mm Hg, compared with reductions of 8.0 and 10.2 mm Hg for aliskiren 150 and 300 mg, respectively (P<0.001), and 11.0 and 13.8 mm Hg for amlodipine 5 and 10 mg, respectively (P<0.05). Aliskiren/amlodipine combinations provided reductions in mean sitting systolic BP 20.6-23.9 mm Hg, compared with decreases of 10.7 and 15.4 mm Hg for aliskiren 150 and 300 mg, respectively (P<0.001), and 15.8 and 21.0 mm Hg for amlodipine 5 (P< or =0.001) and 10 mg (P=NS), respectively. Aliskiren/amlodipine combination therapy provides greater BP lowering than either agent alone, hence offering an effective treatment option for patients with hypertension.

show abstract

Section: Discussionmentioning

confidence: 72%

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study

Littlejohn

Jones²,

Zhang

et al. 2012

J Hum Hypertens

Self Cite

View full text Add to dashboard Cite

show abstract

“…62 First-line therapy with combination aliskiren 150 mg/day or 300 mg/day plus amlodipine 5-10 mg/day provided significantly greater control than the respective monotherapies in patients with stage 2 hypertension. 85 Combination therapy was also more effective than amlodipine monotherapy as first-line therapy in African-American patients with stage 2 hypertension. 86 This was also observed irrespective of age, sex, and the presence of diabetes or obesity.…”

Section: Combination Therapymentioning

confidence: 99%

Role of aliskiren in blood pressure control and renoprotection

Trimarchi

2011

IJNRD

View full text Add to dashboard Cite

Patients with chronic renal disease are at increased risk for the development of cardiovascular disease, which is the main cause of death in this growing population. Among the risk factors involved, hypertension and proteinuria are major contributors to kidney damage and, if not controlled, may eventually lead to the progression of renal failure and end-stage renal disease. Both proteinuria and hypertension can be primary pathologic events or can appear as complications of other disease processes. Initially, these two factors may operate separately but, as progression ensues, both processes generally combine, potentiating their effects and hastening renal damage. Therefore, strategies to reduce blood pressure and proteinuria are essential in order to slow the worsening of many nephropathies. Therapies that target the renin–angiotensin system offer particular benefit, as hypertension and proteinuria can be precisely reduced with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers. However, with this intervention, plasma renin activity remains high, and although primary endpoints may be controlled, elevated renin concentration can contribute to cardiovascular damage. Aliskiren, a direct renin inhibitor, is the first example of a novel class of antihypertensive drugs with potent antiproteinuric effects, which, alone or combined, can contribute to delaying the progression of kidney disease.

show abstract

Aliskiren

Duggan

Chwieduk

Curran

2010

Drugs

View full text Add to dashboard Cite

Aliskiren is an orally administered, nonpeptide direct renin inhibitor indicated for the management of hypertension. Aliskiren was effective in controlling blood pressure (BP) as monotherapy and in combination with other antihypertensives, in large, randomized trials. Aliskiren 150-300 mg/day as monotherapy was effective in lowering BP across short- (≤12 weeks) and longer-term (up to 54 weeks) periods, providing sustained and consistent effects with 24-hour BP control. Compared with other antihypertensives, aliskiren was generally as effective as hydrochlorothiazide (HCTZ), valsartan, losartan, irbesartan and lisinopril in reducing BP. Furthermore, short-term aliskiren was noninferior to ramipril in reducing BP, but with a longer treatment duration, a greater efficacy of aliskiren-based therapy over ramipril-based therapy was demonstrated. Additional BP-lowering effects occurred when aliskiren was coadministered (as a fixed-dose combination or separate tablets) with other antihypertensives, including HCTZ, valsartan and amlodipine, according to large, randomized trials of short- (≤12 weeks) and longer-term (up to 54 weeks) duration. Combination therapy with aliskiren plus HCTZ was effective in hypertensive patients when administered as initial therapy or to patients previously treated with HCTZ or aliskiren monotherapy. Aliskiren-based therapy was also effective in lowering BP in obese patients, patients with type 1 or 2 diabetes mellitus, patients with metabolic syndrome and the elderly. Aliskiren efficacy was observed irrespective of patient age, sex or ethnicity. Aliskiren monotherapy or combination therapy was generally well tolerated over short- and longer-term study durations in large, randomized clinical trials. Clinical trials to evaluate the effects of aliskiren on clinical outcomes, including renoprotective and cardioprotective effects, are currently ongoing. Thus, aliskiren is a useful option for the treatment of patients with stage 1 to stage 2 (mild to moderate) hypertension, alone or in combination with other antihypertensives, including HCTZ, valsartan or amlodipine.

show abstract

First-Line Treatment With Aliskiren/Amlodipine Combination Provides Robust Blood Pressure Reductions in Patients With Severe Hypertension: 9A.06

Cited by 4 publications

References 0 publications

Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study

Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study

Role of aliskiren in blood pressure control and renoprotection

Aliskiren

Contact Info

Product

Resources

About